Docetaxel
- Generic Name
- Docetaxel
- Brand Names
- Taxotere, Docetaxel Accord, Docetaxel Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C43H53NO14
- CAS Number
- 114977-28-5
- Unique Ingredient Identifier
- 699121PHCA
- Background
Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiom...
- Indication
Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy...
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
- Associated Therapies
- -
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
- Conditions
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2023-06-23
- Lead Sponsor
- NuCana plc
- Target Recruit Count
- 91
- Registration Number
- NCT05714553
- Locations
- 🇬🇧
The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇬🇧Queen Elizabeth Hospital University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
🇬🇧Guy's and St Thomas NHS Foundation Trust, London, United Kingdom
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05701007
- Locations
- 🇫🇮
Pfizer, Helsinki, Finland
Study With Immunotherapy Combinations in Participants With Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 320
- Registration Number
- NCT05676931
- Locations
- 🇮🇹
Azienda Sanitaria Territoriale Pesaro Urbino (AST PU), Pesaro, Italy
🇮🇹Fondazione IRCCS Istituto Nazionale dei tumori di Milano, Rome, Italy
🇪🇸Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients
- Conditions
- Interventions
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Jena University Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT05676203
- Locations
- 🇩🇪
Klinikum Nürnberg, Nürnberg, Germany
🇩🇪St. Anna Hospital Herne, Herne, Germany
🇩🇪Universitätsklinikum Gießen und Marburg - Standort Marburg, Marburg, Germany
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
- First Posted Date
- 2023-01-04
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- OncoC4, Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT05671510
- Locations
- 🇦🇺
Bankstown Hospital - 3305, Bankstown, New South Wales, Australia
🇦🇺Newcastle Private Hospital - 3302, New Lambton Heights, New South Wales, Australia
🇦🇺Mater - 3301, Newstead, Queensland, Australia
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT05664971
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study
- Conditions
- Interventions
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- Shanghai Pudong Hospital
- Target Recruit Count
- 204
- Registration Number
- NCT05656079
- Locations
- 🇨🇳
Shanghai Pudong Hospital, Shanghai, China
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
- Conditions
- Interventions
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 139
- Registration Number
- NCT05645380
- Locations
- 🇺🇸
The University of Kansas Cancer Center - Clinical Research Center, Fairway, Kansas, United States
🇺🇸The University of Kansas Cancer Center - Main Hospital, Kansas City, Kansas, United States
🇺🇸The University of Kansas Cancer Center - Westwood, Kansas City, Kansas, United States
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 236
- Registration Number
- NCT05638594
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
- Conditions
- Interventions
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Prelude Therapeutics
- Target Recruit Count
- 186
- Registration Number
- NCT05639751
- Locations
- 🇫🇷
lnstitut Paoli Calmettes, Marseille, France
🇺🇸University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.